Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Yuka Asano1, Shinichiro Kashiwagi1*, Wataru Goto1, Koji Takada1, Katsuyuki Takahashi2, Tamami Morisaki1, Hisakazu Fujita3, Tsutomu Takashima1, Shuhei Tomita2, Masahiko Ohsawa4, Kosei Hirakawa1 and Masaichi Ohira1

Abstract

Background: “Avoiding immune destruction” has recently been established as one of the hallmarks of cancer. The programmed cell death (PD)-1/programmed cell death-ligand (PD-L) 1 pathway is an important immunosuppression mechanism that allows cancer cells to escape host immunity. The present study investigated how the expressions of these immune checkpoint proteins affected responses to neo-adjuvant chemotherapy (NAC) in breast cancer.

Methods: A total of 177 patients with resectable early-stage breast cancer were treated with NAC. Estrogen receptor, progesteron receptor, human epidermal growth factor receptor 2, Ki67, PD-L1, PDL-2 and PD-1 status were assessed by immunohistochemistry.

Results: There were 37 (20.9%) patients with high PD-1 expression, 42 (23.7%) patients had high PD-L1 expression, and 52 (29.4%) patients had high PD-L2 expression. The patients with high PD-1 and PD-L1 expressions had a significantly higher rate of triple-negative breast cancer (TNBC) (p = 0.041) (p < 0.001). In TNBC, patients with high PD-1 and PD-L1 expressions had significantly higher rates of non-pCR (p = 0.003) (p < 0.001). Univariate analysis showed that PD-1 and PD-L1 expressions also significantly shortened disease free survival in TNBC (p = 0.048, HR = 3.318) (p = 0.007, HR = 8.375). However, multivariate analysis found that only PD-L1 expression was an independent prognostic factor (p = 0.041, HR = 9.479).

Conclusions: PD-1 and PD-L1 expressions may be useful as biomarkers to predict treatment responses to NAC in breast cancer. Above all, PD-L1 expression may also be useful as biomarkers for more effective chemotherapy in TNBC.

Keywords: Immune checkpoint, Triple-negative breast cancer, Pathological complete response, Neoadjuvant chemotherapy, PD-1, PD-L1
Background

Various immunosuppressive factors from cancer cells in the tumor microenvironment inhibit host immune responses to cancer [1, 2]. Several immune checkpoints exist in immune response pathways, and negative costimulatory molecules such as cytotoxic T-lymphocyte-associated protein (CTLA)-4 and PD-1 are important checkpoints in limiting self-immune responses [3, 4]. Immunotherapy is effective not only in malignant melanoma and renal cell carcinoma (RCC), but anti-tumor effects have also been demonstrated in a variety of other cancers. Immune checkpoint inhibitor therapy, which turns anti-tumor T cells into effectors, has completely changed the role of cancer immunotherapy in clinical practice [5–8].

Breast cancer was not previously regarded as a tumor associated with abnormal immunity [9]. However, in a phase I trial in TNBC, the PD-1 inhibitor pembrolizumab showed anti-tumor activity, and correlations between PD-1 and PD-L1 (B7-H1) expressions and outcomes were reported [10–13]. Thus, immune checkpoint inhibitor therapy is expected to play a major role in the tailored treatment of breast cancer.

Immunohistological analysis has shown that PD-L1 expression is induced in most solid tumors, including malignant melanoma, ovarian cancer, lung cancer, RCC, and breast cancer. PD-L1 expression in cancer cells has been correlated with cancer progression, the occurrence of metastases, and survival rates [14–17]. In addition, tumor-infiltrating lymphocytes (TILs) include PD-1-positive lymphocytes, and a correlation between them and prognosis in breast cancer has been reported [11].

The effect of the tumor immune environment not only on immunotherapy effectiveness, but also on conventional anti-tumor therapy effectiveness and prognosis, has recently been demonstrated [18]. Thus, improvement of the tumor immune environment is important. In other words, the tumor immune environment plays a role in the anti-tumor effects of conventional anti-tumor drugs. Moreover, immune checkpoint proteins such as PD-1, PD-L1, and PD-L2 (B7-H2) may play an important role in improving the tumor immune environment. Given this background, the clinical significance of immune checkpoint protein expression was investigated in patients receiving NAC for breast cancer using conventional anti-cancer drugs, and whether this would be useful as a marker to predict treatment response was evaluated.

Methods

Patient background

A total of 177 patients with resectable, early-stage breast cancer diagnosed as stage IIA (T1, N1, M0 or T2, N0, M0), IIB (T2, N1, M0 or T3, N0, M0), or IIIA (T1-2, N2, M0 or T3, N1-2, M0) were treated with NAC between 2007 and 2013. Tumor stage and T and N factors were stratified based on the TNM Classification of Malignant Tumors, UICC Sixth Edition [19]. Breast cancer was confirmed histologically by core needle biopsy and staged by systemic imaging studies using computed tomography (CT), ultrasonography (US), and bone scintigraphy. Breast cancer was classified into subtypes according to the immunohistochemical expression of ER, PgR, HER2, and Ki67. Based on their immunohistochemical expression, the tumours are categorized into the immunophenotypes luminal A (ER+ and/or PgR+, HER2−, Ki67-low), luminal B (ER+ and/or PgR+, HER2+) (ER+ and/or PgR+, HER2−, Ki67-high), HER2-enriched (ER−, PgR−, and HER2+), and TNBC (negative for ER, PgR and HER2) [20]. In this study, HER2-enriched and luminal B (ER+ and/or PgR+, HER2+) were considered as HER2-positive breast cancer (HER2+BC).

All patients received a standardized protocol of NAC consisting of four courses of FEC100 (500 mg/m² fluorouracil, 100 mg/m² epirubicin, and 500 mg/m² cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m² paclitaxel administered weekly [21, 22]. Forty-five patients had HER2+BC and were additionally administered weekly 2 mg/kg or tri-weekly (6 mg/kg) trastuzumab during paclitaxel treatment [23]. All patients underwent chemotherapy as outpatients. Therapeutic anti-tumor effects were assessed according to the response evaluation criteria in solid tumors (RECIST) criteria [24]. Pathological complete response (pCR) was defined as the complete disappearance of the invasive compartment of the lesion with or without intraductal components, including in the lymph nodes. Patients underwent mastectomy or breast-conserving surgery after NAC. All patients who underwent breast-conserving surgery were administered postoperative radiotherapy to the remnant breast. Overall survival (OS) time was the period from the initiation of NAC to the time of death from any cause. Disease-free survival (DFS) was defined as freedom from all local, loco-regional, and distant recurrences. All patients were followed up by physical examination every 3 months, US every 6 months, and CT and bone scintigraphy annually. The median follow-up period for the assessment of OS was 3.4 years (range 0.6–6.0 years), and for DFS it was 3.1 years (range 0.1–6.0 years). This study has been conducted in our institution, Osaka City University Graduate School of Medicine, Osaka, Japan, according to the reporting recommendations for tumor marker prognostic studies (REMARK) guidelines and a retrospectively written research, pathological evaluation, and statistical plan [25].
Immunohistochemistry
All patients underwent a core needle biopsy prior to NAC, and they underwent curative surgery involving a mastectomy or conservative surgery with axillary lymph node dissection after NAC at the Osaka City University. Immunohistochemical studies were performed as previously described on core needle biopsy specimens [26]. Tumour specimens were fixed in 10% formaldehyde solution and embedded in paraffin (FFPE), and 4-µm-thick sections were mounted onto glass slides. Slides were deparaffinized in xylene and heated for 20 min (105 °C, 0.4 kg/m²) in an autoclave in Target Retrieval Solution (Dako, Carpinteria, CA, USA). Specimens were then incubated with 3% hydrogen peroxide in methanol for 15 min to block the endogenous peroxidase activity, then incubated in 10% normal goat or rabbit serum to block non-specific reactions.

Primary monoclonal antibodies directed against ER (clone 1D5, dilution 1:80; Dako, Cambridge, UK), PgR (clone PgR636, dilution 1:100; Dako), HER2 (HercepT-est™; Dako), Ki67 (clone MIB-1, dilution 1:100; Dako), PD-1 (clone NAT105, dilution 1:100; Abcam, Cambridge, UK), PD-L1 (clone 27A2, dilution 1:100; MBL, Nagoya, Japan), and PD-L2 (clone #176611, dilution 1:100; R&D Systems, Minneapolis, MN) were used. Tissue sections were incubated with each antibody for 70 min at room temperature or overnight at 4 °C, then incubated with horseradish peroxidase-conjugated anti-rabbit or antimouse Ig secondary antibodies (HISTOFINE (PO)™ kit; Nichirei, Tokyo, Japan). Slides were subsequently treated with streptavidin-peroxidase reagent and incubated in phosphate-buffered saline-diaminobenzidine and 1% hydrogen peroxide (v/v), followed by counterstaining with Mayer’s haematoxylin. Positive and negative controls were carried out on FFPE lymph node tissues using corresponding monoclonal antibody and mouse isotype IgG.

Immunohistochemical scoring
Immunohistochemical scoring was performed by two pathologists specialized in mammary gland pathology, using the blind method to confirm the objectivity and reproducibility of diagnosis. The cut-off value for ER and PgR positivity was set at ≥1% in accordance with previous studies [27]. HER2 expression was scored according to the accepted grading system (0, no reactivity, or membranous reactivity in less than 10% of cells; 1+, faint/barely perceptible membranous reactivity in ≥10% of cells or reactivity in only part of the cell membrane; 2+, weak to moderate complete or basolateral membranous reactivity in ≥10% of tumour cells; or 3+, strong complete or basolateral membranous reactivity in ≥10% of tumour cells). HER2 expression was considered positive if the immunostaining score was 3+, or in cases where the score was 2+ and included gene amplification via fluorescent in situ hybridization (FISH). For FISH analyses, each copy of the HER2 gene and its centromere 17 (CEP17) reference were counted. The interpretation followed the criteria of the ASCO/CAP guidelines for HER2 IHC classification for breast cancer: positive if the HER2/CEP17 ratio was higher than 2.0 [28]. A Ki67-labeling index ≥14% was classified as positive [20].

Histopathologic analysis of TILs was evaluated on a single full-face hematoxylin and eosin (HE)-stained tumor section using criteria described [29–31]. To evaluate PD-1 expression, five stained areas were selected, and the number of TILs in stroma surrounding the stained cancer cells was quantitatively measured in each field under 400-times magnification (Fig. 1a). The median value of the average each field was determined, and that number was set as a cutoff value. To evaluate PD-L1 and PD-L2 expression, 3 fields of view (FOVs) in darkly stained areas were selected, and the percentage of cancer cells stained with anti-PD-L1 antibody and anti-PD-L2 antibody in each FOVs was measured under 400-times magnification.
magnified microscopy (Fig. 1b, c). Based on previous reports, ≥ 10% was defined as high expression, and <10% was defined as low expression [12, 32].

Statistical analysis
Statistical analysis was performed using the SPSS version 19.0 statistical software package (IBM, Armonk, NY). The associations between PD-1, PD-L1 and PD-L2 and clinicopathological variables were evaluated using χ² tests. Multivariate analysis of pCR was carried out using a binary logistic regression model. The Kaplan–Meier method was used to estimate DFS and OS, and the results were compared between groups using log-rank tests. Multivariate analysis of prognostic factors was carried out using a Cox regression model. A p value < 0.05 was considered significant. Cutoff values for different biomarkers included in this study were chosen before the statistical analysis.

Results
Clinicopathological responses of primary breast cancers to NAC
The subtype in 177 patients who received NAC was TNBC in 61 (34.5%) patients and HER2⁺ BC in 45 (25.4%) patients. Regarding treatment response, 67 (37.9%) patients had a pCR, and 110 (62.1%) patients had a non-pCR. Regarding treatment response, 67 (37.9%) patients had a pCR, and 110 (62.1%) patients had a non-pCR. According to subtype, 28 (45.9%) TNBC patients and 18 (40.0%) HER2⁺ BC patients had a pCR.

Immune checkpoint protein expression in all breast cancers
TIL PD-1 expression ranged from 0 to 68. The median value of the average in 3 FOVs was 6. There were 37 (20.9%) patients with high PD-1 expression (≥ 6) and 140 (79.1%) patients with low PD-1 expression (<6). In addition, 42 (23.7%) patients had high PD-L1 expression, and 52 (29.4%) patients had high PD-L2 expression.

Evaluation based on clinicopathologic features showed that patients with high PD-1 and PD-L1 expressions had a significantly higher rate of TNBC (p = 0.041) (p < 0.001) and HER2⁺ BC (p = 0.004) (p = 0.004). Patients with PD-L1 expression had a significantly higher rate of non-pCR (p <0.001), and PD-1 and PD-L2 expressions were greater (p <0.001) (p <0.001) (Table 1). There were no significant differences for other clinicopathologic features.

DFS was significantly longer in patients with low, compared to high, PD-1 and PD-L1 expressions (p = 0.006, log-rank) (p = 0.001, log-rank) (Fig. 2a, b). OS was also significantly longer in patients with low, compared to high, PD-1 and PD-L1 expressions (p = 0.048, log-rank) (p = 0.022, log-rank) (Additional file 1: Fig. S1A, B). DFS and OS did not differ significantly between patients with low vs high PD-L2 expression (p = 0.657, log-rank) (p = 0.615, log-rank) (Fig. 2c) (Additional file 1: Fig. S1C).

Univariate analysis showed that PD-1 and PD-L1 expressions were associated with significantly shorter DFS (p = 0.008, HR = 2.752) (p = 0.002, HR = 3.194). However, although multivariate analysis showed that lymph node metastases were an independent poor prognostic factor (p = 0.046, HR = 4.330), PD-1 and PD-L1 expressions were not independent prognostic factors (p = 0.492, HR = 1.415) (p = 0.084, HR = 2.613) (Table 2).

Immune checkpoint protein expression in triple-negative breast cancer
Among the 61 patients with TNBC, 18 (29.5%) had high PD-1 expression, 24 (39.3%) had high PD-L1 expression, and 20 (32.8%) had high PD-L2 expression. Analysis of clinicopathologic features showed that the high PD-1 expression group was significantly older (p = 0.016), and that patients with high PD-L1 expression had a significantly lower Ki67 index (p = 0.005). Patients with high PD-1 and PD-L1 expressions had significantly higher rates of non-pCR (p = 0.003) (p <0.001). PD-1 expression was significantly correlated with PD-L1 expression (p < 0.001), it but was not correlated with PD-L2 expression (Table 3).

Analysis of outcomes showed that DFS was significantly longer in patients with low, compared to patients with high, PD-1 and PD-L1 expressions (p = 0.036, log-rank) (p = 0.001, log-rank) (Fig. 3a, b). OS was also significantly longer in patients with low, compared to patients with high, PD-1 expression (p = 0.021, log-rank), but OS was not significantly different based on PD-L1 expression (p = 0.155, log-rank) (Additional file 1: Fig. S1D, E). DFS and OS were also not significantly different based on PD-L2 expression (p = 0.665, log-rank) (p = 0.595, log-rank) (Fig. 3c) (Additional file 1: Fig. S1F).

Univariate analysis showed that PD-1 and PD-L1 expressions also significantly shortened DFS in TNBC (p = 0.048, HR = 3.318) (p = 0.007, HR = 8.375). However, multivariate analysis found that only PD-L1 expression was an independent prognostic factor (p = 0.041, HR = 9.479) (Table 4).

Immune checkpoint protein expression in HER2-positive breast cancer
Among the 45 patients with HER2⁺ BC, 3 (6.7%) had high PD-1 expression, 4 (8.9%) had high PD-L1 expression, and 16 (35.6%) had high PD-L2 expression. Analysis of clinicopathologic features showed that the patients with high PD-L2 expressions had significantly higher rates of pCR (p = 0.005). PD-1 expression was significantly correlated with PD-L1 expression (p < 0.001) and PD-L2 expression (p = 0.039). And, PD-L1 expression was
significantly correlated with PD-L2 expression ($p = 0.012$) (Table 3).

Analysis of outcomes showed that DFS was not significantly longer in patients with low, compared to patients with high, PD-1, PD-L1 and PD-L2 expressions ($p = 0.632$, $p = 0.556$, $p = 0.421$, log-rank, respectively) (Fig. 3d–f). OS was also not significantly longer in patients with low, compared to patients with high, PD-1, PD-L1 and PD-L2 expressions ($p = 0.673$, $p = 0.620$, $p = 0.749$, log-rank, respectively) (Additional file 1: Fig. S1G–I). Univariate and multivariate analysis, no factors contributing to DFS were observed (Table 4).

**Table 1** Correlation between clinicopathological features and PD-1, PD-L1, and PD-L2 expression in 177 all breast cancers

| Parameters                        | PD-1 Positive (n = 37) | PD-1 Negative (n = 140) | p value | PD-L1 Positive (n = 42) | PD-L1 Negative (n = 135) | p value | PD-L2 Positive (n = 53) | PD-L2 Negative (n = 124) | p value |
|-----------------------------------|------------------------|-------------------------|---------|-------------------------|--------------------------|---------|-------------------------|--------------------------|---------|
| **Intrinsic subtype**             |                        |                         |         |                        |                          |         |                        |                          |         |
| TNBC                              | 18 (48.6%)             | 43 (30.7%)              | 0.041   | 24 (57.1%)              | 37 (27.4%)               | < 0.001 | 20 (37.7%)              | 41 (33.1%)               | 0.549   |
| Non-TNBC                          | 19 (51.4%)             | 97 (69.3%)              |         | 18 (42.9%)              | 98 (72.6%)               |         | 33 (62.3%)              | 83 (66.9%)               |         |
| **Intrinsic subtype**             |                        |                         |         |                        |                          |         |                        |                          |         |
| HER2+ BC                          | 3 (81.1%)              | 42 (30.0%)              | 0.004   | 4 (9.5%)                | 41 (30.4%)               | 0.004   | 16 (30.2%)              | 29 (23.4%)               | 0.341   |
| Non-HER2+ BC                      | 34 (18.9%)             | 98 (70.0%)              |         | 38 (90.5%)              | 94 (69.6%)               |         | 37 (69.8%)              | 95 (76.6%)               |         |
| **Age at operation**              |                        |                         |         |                        |                          |         |                        |                          |         |
| ≤ 56                              | 15 (40.5%)             | 72 (51.4%)              | 0.239   | 20 (47.6%)              | 67 (49.6%)               | 0.820   | 28 (52.8%)              | 59 (47.6%)               | 0.522   |
| > 56                              | 22 (59.5%)             | 68 (48.6%)              |         | 22 (52.4%)              | 68 (50.4%)               |         | 25 (47.2%)              | 65 (52.4%)               |         |
| **Menopause**                     |                        |                         |         |                        |                          |         |                        |                          |         |
| Negative                          | 14 (37.8%)             | 58 (41.4%)              | 0.693   | 18 (42.9%)              | 54 (40.0%)               | 0.742   | 23 (43.4%)              | 49 (39.5%)               | 0.630   |
| Positive                          | 23 (62.2%)             | 82 (58.6%)              |         | 24 (57.1%)              | 81 (60.0%)               |         | 30 (56.6%)              | 75 (60.5%)               |         |
| **Tumor size (cm)**               |                        |                         |         |                        |                          |         |                        |                          |         |
| ≤ 2                               | 5 (13.5%)              | 19 (13.6%)              | 0.993   | 6 (14.3%)               | 18 (13.3%)               | 0.875   | 9 (17.0%)               | 15 (12.1%)               | 0.385   |
| > 2                               | 32 (86.5%)             | 121 (86.4%)             |         | 36 (85.7%)              | 117 (86.7%)              |         | 44 (83.0%)              | 109 (87.9%)              |         |
| **Lymph node status**             |                        |                         |         |                        |                          |         |                        |                          |         |
| Negative                          | 7 (18.9%)              | 34 (24.3%)              | 0.491   | 10 (23.8%)              | 31 (23.0%)               | 0.910   | 12 (22.6%)              | 29 (23.4%)               | 0.914   |
| Positive                          | 30 (81.1%)             | 106 (75.7%)             |         | 32 (76.2%)              | 104 (77.0%)              |         | 41 (77.4%)              | 95 (76.6%)               |         |
| **Nuclear grade**                 |                        |                         |         |                        |                          |         |                        |                          |         |
| 1, 2                              | 26 (70.3%)             | 111 (79.3%)             | 0.244   | 31 (73.8%)              | 106 (78.5%)              | 0.524   | 39 (73.6%)              | 98 (79.0%)               | 0.427   |
| 3                                 | 11 (29.7%)             | 29 (20.7%)              |         | 11 (26.2%)              | 29 (21.5%)               |         | 14 (26.4%)              | 26 (21.0%)               |         |
| Ki67                              |                        |                         |         |                        |                          |         |                        |                          |         |
| ≤ 14%                             | 13 (35.1%)             | 61 (43.6%)              | 0.355   | 16 (38.1%)              | 58 (43.0%)               | 0.576   | 18 (34.0%)              | 56 (45.2%)               | 0.167   |
| > 14%                             | 24 (64.9%)             | 79 (56.4%)              |         | 26 (61.9%)              | 77 (57.0%)               |         | 35 (66.0%)              | 68 (54.8%)               |         |
| **Pathological response**         |                        |                         |         |                        |                          |         |                        |                          |         |
| pCR                               | 9 (24.3%)              | 58 (41.4%)              | 0.056   | 6 (14.3%)               | 61 (45.2%)               | < 0.001 | 24 (45.3%)              | 43 (34.7%)               | 0.183   |
| Non-pCR                           | 28 (75.7%)             | 82 (58.6%)              |         | 36 (85.7%)              | 74 (54.8%)               |         | 29 (54.7%)              | 81 (65.3%)               |         |
| PD-1                              |                        |                         |         |                        |                          |         |                        |                          |         |
| Negative                          | Not determined         | Not determined          |         | 13 (31.0%)              | 29 (69.0%)               | < 0.001 | 31 (58.5%)              | 109 (87.9%)              | < 0.001 |
| Positive                          | Not determined         | Not determined          |         | 127 (94.1%)             | 8 (5.9%)                 |         | 22 (41.5%)              | 15 (12.1%)               | < 0.001 |
| PD-L1                             |                        |                         |         |                        |                          |         |                        |                          |         |
| Negative                          | 8 (21.6%)              | 127 (90.7%)             | < 0.001 | Not determined          | Not determined           |         | 25 (47.2%)              | 110 (88.7%)              | < 0.001 |
| Positive                          | 29 (78.4%)             | 13 (9.3%)               |         | 14 (33.3%)              | 28 (66.7%)               | < 0.001 | 28 (52.8%)              | 14 (11.3%)               |         |
| PD-L2                             |                        |                         |         |                        |                          |         |                        |                          |         |
| Negative                          | 15 (40.5%)             | 109 (77.9%)             | < 0.001 | 14 (33.3%)              | 110 (81.5%)              | < 0.001 | Not determined          | Not determined           |         |
| Positive                          | 22 (59.5%)             | 31 (22.1%)              |         | 28 (66.7%)              | 25 (18.5%)               | < 0.001 | Not determined          | Not determined           |         |

TNBC: triple-negative breast cancer, HER2: human epidermal growth factor receptor 2, BC: breast cancer, pCR: pathological complete response, PD-1: programmed cell death-1, PD-L1: programmed cell death-ligand.
Discussion
Stephen Paget in 1889 proposed the “seed and soil” theory with regard to cancer metastases, and since that time, the importance of the tumor microenvironment in cancer cell proliferation has been increasingly recognized [33]. Tumor tissue is composed not only of cancer cells, but also inflammatory cells, immunocytes, vascular and lymphatic cells, fibroblasts, and fibrous tissue, and these comprise the characteristic tumor microenvironment. The tumor immune environment affects not only the effectiveness of immunotherapy, but also the prognosis and response to other treatments, such as conventional anti-tumor drugs [18]. Thus, control and improvement of the tumor immune microenvironment are important. In other words, assessment of the tumor immune environment in each individual patient can be useful in predicting treatment responses to conventional anti-cancer drugs. Therefore, the present study investigated the immune microenvironment in breast cancer patients’ tumor tissues before receiving NAC and examined the correlation with treatment responses.

“Avoiding immune destruction” has recently been established as one of the hallmarks of cancer [33]. Cancer is controlled by immunological surveillance mechanisms at the stage of cancer cell growth and by immune responses to tumor antigens in actual cancer tissue [2]. In response to these immune responses, cancer cells themselves can alter their immunogenicity and induce immunosuppression mechanisms in the tumor microenvironment, thus enabling cancer cells to cleverly escape the host immune system, survive, and grow [1, 34].

The PD-1/PD-L1 pathway is also an important immunosuppression mechanism that allows cancer cells to escape host immunity. Because of excessive PD-1 and PD-L1 levels in the tumor microenvironment, antibody inhibition of PD-1 and PD-L1 pathways is promising.
Table 3 Correlation between clinicopathological features and PD-1, PD-L1, and PD-L2 expression in 61 triple-negative and 45 HER2-positive breast cancers

| Parameters | PD-1 | PD-L1 | PD-L2 |
|------------|------|-------|-------|
|            | Positive | Negative | p value | Positive | Negative | p value | Positive | Negative | p value |
| TNBC (n=61) | | | | | | | | | |
| Age at operation | | | | | | | | | |
| ≤ 56 | 4 (22.2%) | 24 (55.8%) | 0.016 | 10 (41.7%) | 18 (48.6%) | 0.593 | 12 (60.0%) | 16 (39.0%) | 0.123 |
| > 56 | 14 (77.8%) | 19 (44.2%) | | 14 (58.3%) | 19 (51.4%) | | 8 (40.0%) | 25 (61.0%) | |
| Menopause | | | | | | | | | |
| Negative | 4 (22.2%) | 18 (41.9%) | 0.121 | 9 (37.5%) | 13 (35.1%) | 0.851 | 8 (40.0%) | 14 (34.1%) | 0.655 |
| Positive | 14 (77.8%) | 25 (58.1%) | | 15 (62.5%) | 24 (64.9%) | | 12 (60.0%) | 27 (65.9%) | |
| Tumor size (cm) | | | | | | | | | |
| ≤ 2 | 3 (16.7%) | 4 (9.3%) | 0.337 | 3 (12.5%) | 4 (10.8%) | 0.573 | 3 (15.0%) | 4 (9.8%) | 0.416 |
| > 2 | 15 (83.3%) | 39 (90.7%) | | 21 (87.5%) | 33 (89.2%) | | 17 (85.0%) | 37 (90.2%) | |
| Lymph node status | | | | | | | | | |
| Negative | 3 (16.7%) | 8 (18.6%) | 0.586 | 5 (20.8%) | 6 (16.2%) | 0.647 | 3 (15.0%) | 8 (19.5%) | 0.481 |
| Positive | 15 (83.3%) | 35 (81.4%) | | 19 (79.2%) | 31 (83.8%) | | 17 (85.0%) | 33 (80.5%) | |
| Nuclear grade | | | | | | | | | |
| 1, 2 | 13 (72.2%) | 31 (72.1%) | 0.992 | 19 (79.2%) | 25 (67.6%) | 0.324 | 14 (70.0%) | 30 (73.2%) | 0.795 |
| 3 | 5 (27.8%) | 12 (27.9%) | | 5 (20.8%) | 12 (32.4%) | | 6 (30.0%) | 11 (26.8%) | |
| Ki67 | | | | | | | | | |
| ≤ 14% | 6 (33.3%) | 12 (27.9%) | 0.672 | 12 (50.0%) | 6 (16.2%) | 0.005 | 6 (30.0%) | 12 (29.3%) | 0.953 |
| > 14% | 12 (66.7%) | 31 (72.1%) | | 12 (50.0%) | 31 (83.8%) | | 14 (70.0%) | 29 (70.7%) | |
| Pathological response | | | | | | | | | |
| pCR | 3 (16.7%) | 25 (58.1%) | 0.003 | 3 (12.5%) | 25 (67.6%) | <0.001 | 10 (50.0%) | 18 (43.9%) | 0.654 |
| Non-pCR | 15 (83.3%) | 18 (41.9%) | | 21 (87.5%) | 12 (32.4%) | | 10 (50.0%) | 23 (56.1%) | |
| PD-1 | | | | | | | | | |
| Negative | Not determined | Not determined | | | | | | | |
| Positive | 9 (37.5%) | 34 (91.9%) | 0.001 | 12 (60.0%) | 31 (75.6%) | 0.210 |
| PD-L1 | | | | | | | | | |
| Negative | 3 (16.7%) | 34 (48.4%) | <0.001 | Not determined | Not determined | | 10 (50.0%) | 27 (65.9%) | 0.234 |
| Positive | 15 (83.3%) | 9 (51.6%) | | | | | 10 (50.0%) | 14 (34.1%) | |
| PD-L2 | | | | | | | | | |
| Negative | 10 (55.6%) | 31 (79.1%) | 0.210 | 14 (58.3%) | 27 (73.0%) | 0.234 |
| Positive | 8 (44.4%) | 12 (20.9%) | | 10 (41.7%) | 10 (27.0%) | | Not determined | Not determined | |

| Parameters | PD-1 | PD-L1 | PD-L2 |
|------------|------|-------|-------|
|            | Positive | Negative | p value | Positive | Negative | p value | Positive | Negative | p value |
| HER2+BC (n=45) | | | | | | | | | |
| Age at operation | | | | | | | | | |
| ≤ 56 | 0 (0.0%) | 20 (47.6%) | 0.162 | 1 (25.0%) | 19 (46.3%) | 0.394 | 6 (37.5%) | 14 (48.3%) | 0.486 |
| > 56 | 3 (100.0%) | 22 (52.4%) | | 3 (75.0%) | 22 (53.7%) | | 10 (62.5%) | 15 (51.7%) | |
| Menopause | | | | | | | | | |
| Negative | 0 (0.0%) | 18 (42.9%) | 0.206 | 1 (25.0%) | 17 (41.5%) | 0.471 | 6 (37.5%) | 12 (41.4%) | 0.799 |
| Positive | 3 (100.0%) | 24 (57.1%) | | 3 (75.0%) | 24 (58.5%) | | 10 (62.5%) | 17 (58.6%) | |
| Tumor size (cm) | | | | | | | | | |
| ≤ 2 | 1 (33.3%) | 5 (11.9%) | 0.356 | 1 (25.0%) | 5 (12.2%) | 0.448 | 4 (25.0%) | 2 (6.9%) | 0.107 |
| > 2 | 2 (66.7%) | 37 (88.1%) | | 3 (75.0%) | 36 (87.8%) | | 12 (75.0%) | 27 (93.1%) | |
for effectively reversing this immunosuppression in the tumor microenvironment [32]. Suppression of T cell activation by PD-1 signals is promoted in association with the interaction of PD-1 and its ligands PD-L1 and PD-L2 [4, 35, 36]. The present study found statistical correlations among PD-1, PD-L1, and PD-L2 expressions in all breast cancers. There might be an interaction between PD-1 and its ligand PD-L1 and PD-L2.

The present study also investigated how the expressions of these immune checkpoint proteins affected responses to NAC in breast cancer. Previous studies have shown that high, compared to low, PD-1 expression is associated with a poorer prognosis in malignant melanoma, RCC, and breast cancer [10, 11, 37]. Moreover, more reports about PD-L1 than about PD-1 suggest a correlation between PD-L1 expression and the degree of cancer malignancy and a poorer prognosis [12, 14–16]. In TNBC, PD-1 and PD-L1 expression has been reported frequently in TNBC [1, 12]. In the present study, patients with high PD-1 and PD-L1 expressions had significantly higher rates of TNBC. In addition, patients with low PD-1 and PD-L1 expressions had a significantly longer DFS. In particular, low PD-1 and PD-L1 expressions in TNBC were associated with a higher pCR rate and significantly longer DFS, and low PD-L1 expression was an independent prognostic factor. These results suggest that immune escape mediated by immune checkpoints may play a role in the biological malignancy of TNBC. Among patients who received NAC, a longer DFS in patients with low PD-L1 expression suggests increased chemotherapy sensitivity. However, as limitation of this study, it is thought that pCR which has an influence on the prognosis of TNBC after NAC was included as a factor [38, 39]. On the other hand, although HER2⁺BC showed correlation with PD-1 and PD-L1 expression, there was no effect on prognosis.

Many anti-cancer drugs have immunosuppressive effects and are not compatible with immunotherapy, but depending on their mode of administration, immunological enhancement or reversal of immunosuppression

| Parameters                  | PD-1 Positive (n = 3) | Negative (n = 42) | p value | PD-L1 Positive (n = 4) | Negative (n = 41) | p value | PD-L2 Positive (n = 16) | Negative (n = 29) | p value |
|-----------------------------|-----------------------|-------------------|---------|------------------------|-------------------|---------|-------------------------|-------------------|---------|
| Lymph node status           |                       |                   |         |                        |                   |         |                         |                   |         |
| Negative                    | 1 (33.3%)             | 15 (35.7%)        | 0.715   | 2 (50.0%)              | 14 (34.2%)        | 0.448   | 5 (31.3%)               | 11 (37.9%)        | 0.455   |
| Positive                    | 2 (66.7%)             | 27 (64.3%)        |         | 2 (50.0%)              | 27 (65.8%)        |         | 11 (68.7%)              | 18 (62.1%)        |         |
| Nuclear grade               |                       |                   |         |                        |                   |         |                         |                   |         |
| 1, 2                        | 2 (66.7%)             | 33 (78.6%)        | 0.539   | 2 (50.0%)              | 33 (80.5%)        | 0.209   | 12 (75.0%)              | 23 (79.3%)        | 0.508   |
| 3                           | 1 (33.3%)             | 9 (21.4%)         |         | 2 (50.0%)              | 8 (19.5%)         |         | 4 (25.0%)               | 6 (20.7%)         |         |
| Ki67                         |                       |                   |         |                        |                   |         |                         |                   |         |
| ≤14%                        | 1 (33.3%)             | 23 (54.8%)        | 0.449   | 1 (25.0%)              | 23 (56.1%)        | 0.254   | 7 (43.8%)               | 17 (58.6%)        | 0.338   |
| >14%                        | 2 (66.7%)             | 19 (45.2%)        |         | 3 (75.0%)              | 18 (43.9%)        |         | 9 (56.2%)               | 12 (41.4%)        |         |
| Pathological response       |                       |                   |         |                        |                   |         |                         |                   |         |
| pCR                          | 0 (0.0%)              | 18 (42.9%)        | 0.206   | 1 (25.0%)              | 17 (41.5%)        | 0.471   | 11 (62.5%)              | 7 (24.1%)         | 0.005   |
| Non-pCR                      | 3 (100.0%)            | 24 (57.1%)        |         | 3 (75.0%)              | 24 (58.5%)        |         | 5 (37.5%)               | 22 (75.9%)        |         |
| PD-1                         |                       |                   |         |                        |                   |         |                         |                   |         |
| Negative                    | Not determined         | Not determined    |         | 1 (25.0%)              | 41 (100.0%)       | < 0.001 | 13 (81.3%)              | 29 (100.0%)       | 0.039   |
| Positive                    |                         |                   |         | 3 (75.0%)              | 0 (0.0%)          |         | 3 (18.7%)               | 0 (0.0%)          |         |
| PD-L1                        |                       |                   |         |                        |                   |         |                         |                   |         |
| Negative                    | 0 (0.0%)              | 41 (97.6%)        | < 0.001 | Not determined          | Not determined    |         | 12 (75.0%)              | 29 (100.0%)       | 0.012   |
| Positive                    |                         |                   |         |                         |                   |         | 4 (25.0%)               | 0 (0.0%)          |         |
| PD-L2                        |                       |                   |         |                        |                   |         |                         |                   |         |
| Negative                    | 0 (0.0%)              | 29 (69.0%)        | 0.039   | 0 (0.0%)               | 29 (70.7%)        | 0.012   | Not determined          | Not determined    |         |
| Positive                    |                         |                   |         | 3 (100.0%)             | 13 (31.0%)        |         | 4 (100.0%)              | 12 (29.3%)        |         |

TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand.
is possible [40, 41]. In the present study, a standard regimen (FEC followed by paclitaxel ± trastuzumab) was used as NAC in breast cancer. To improve immune escape on the cancer cell side, decreased sensitivity to cytotoxic T lymphocytes (CTLs) can be improved by drugs such as 5FU and paclitaxel, and so-called immunogenic cell death (ICD) of cancer cells can be induced by alkylating agents such as cyclophosphamide and anthracycline drugs [40, 42]. Moreover, to improve immune escape on the host side, paclitaxel inhibition of regulatory T cells (Tregs) and 5FU inhibition of myeloid-derived suppressor cells (MDSCs) have been reported [40, 42]. Such regimens are thought to enhance immune responses by these mechanisms. Furthermore, improvement of immune escape on the cancer cell side by PD-L1 inhibition and on the host side by PD-1 inhibition can enhance the anti-tumor effects of anti-cancer drugs.

Fig. 3 Analysis of the correlation with outcome of 61 TNBC and 45 HER2+ BC patients. In 61 TNBC cases, DFS was significantly longer in patients with low, compared to high, PD-1 and PD-L1 expressions (p = 0.001, log-rank) (p = 0.036, log-rank) (a, b). DFS did not differ significantly between patients with low vs high PD-L2 expression (p = 0.665, log-rank) (c). In 45 HER2+ BC cases, DFS was not significantly longer in patients with low, compared to patients with high, PD-1, PD-L1 and PD-L2 expressions (p = 0.632, p = 0.556, p = 0.421, log-rank, respectively) (d, e, f)
Conclusions
In conclusion, PD-1 and PD-L1 expressions may be useful as biomarkers to predict treatment responses to NAC in breast cancer. Above all, PD-L1 expression may also be useful as biomarkers for more effective chemotherapy in TNBC.

Additional file

Additional file 1: Fig S1. Overall survival analysis of the correlation with outcome. Analysis of the correlation with outcome of all 177 patients, overall survival (OS) was also significantly longer in patients with low, compared to high, PD-1 and PD-L1 expressions (p = 0.048, log-rank) (A, B). OS did not differ significantly between patients with low vs high PD-L2 expression (p = 0.615, log-rank) (C). In 61 TNBC cases, OS was also significantly longer in patients with low, compared to patients with high, PD-1 expression (p = 0.021, log-rank) (D, E). DFS and OS were also not significantly different based on PD-L1 expression (p = 0.155, log-rank) (D, E). In 45 HER2+BC cases, OS was also not significantly longer in patients with low, compared to patients with high, PD-1, PD-L1 and PD-L2 expressions (p = 0.673, p = 0.620, p = 0.749, log-rank, respectively) (G-I).

Abbreviations
CTLA: cytotoxic T-lymphocyte-associated protein; PD: programmed cell death; RCC: renal cell carcinoma; TNBC: triple-negative breast cancer; PD-L: programmed cell death-ligand; TILs: tumor-infiltrating lymphocytes; NAC: neoadjuvant chemotherapy; CT: computed tomography; US: ultrasonography; ER: estrogen receptor; PR: progesterone receptor; HER: human epidermal growth factor receptor; HER2+BC: HER2-positive breast cancer; RECIST: response evaluation criteria in solid tumors; pCR: pathological complete response; OS: overall survival; DFS: disease-free survival; FISH: fluorescent in situ hybridization; CEP: centromere; FOVs: fields of view; CTLs: cytotoxic T lymphocytes; ICD: immunogenic cell death; Tregs: regulatory T cells; MDSCs: myeloid-derived suppressor cells.

Authors’ contributions
YA participated in the design of the study and drafted the manuscript. SK participated in the design of the study and manuscript editing. WG, KTakad, TM and TT helped with study data collection and manuscript preparation. KTakah, HF and ST helped with study data collection and participated in its design. MOhs helped with pathological diagnosis. KH and MOhi conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 2 Department of Pharmacology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 3 Department of Scientific and Linguistic Fundamentals of Nursing, Osaka City University Graduate School of Nursing, 1-5-17 Asahi-machi, Abeno-ku, Osaka 545-0051, Japan.

Table 4 Univariate and multivariate analysis with respect to progression free survival in 61 triple-negative and 45 HER2-positive breast cancers

| Parameters | Univariate analysis | Multivariate analysis |
|------------|---------------------|----------------------|
|            | Hazard ratio 95% CI | p value              |
| TNBC (n = 61) |                      |                      |
| Lymph node status |                |                      |
| Positive vs negative | 0.942 0.203–4.359 | 0.839              |
| ≤ 14% vs > 14% | 0.739 0.216–2.526 | 0.630               |
| Pathological response | 0.234 0.050–1.084 | 0.063               |
| pCR vs non-pCR PD-1 | 3.318 1.011–10.891 | 0.048               |
| Positive vs negative PD-L1 | 8.375 1.807–38.812 | 0.007               |
| HER2+BC (n = 45) |                      |                      |
| Lymph node status | 0.603 0.318–1.145 | 0.122               |
| ≤ 14% vs > 14% | 0.714 0.385–1.326 | 0.286               |
| Pathological response | 0.670 0.358–1.254 | 0.210               |
| pCR vs non-pCR PD-1 | 1.990 0.585–6.766 | 0.271               |
| Positive vs negative PD-L1 | 1.934 0.651–5.738 | 0.235               |

TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, CI confidence interval, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand.
Kashiwagi.

Acknowledgements
We thank Hitoshi Nishikawa (Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center) for helpful advice regarding antibodies of immunohistochemistry. And, we thank Yayoi Matsukiyo and Tomomi Okawa (Department of Surgical Oncology, Osaka City University Graduate School of Medicine) for helpful advice regarding data management.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets supporting the conclusions of this article is included within the article.

Consent for publication
Written informed consent was obtained from all patients.

Ethics approval and consent to participate
Written informed consent was obtained from all subjects. This research conformed to the provisions of the Declaration of Helsinki in 2013. All patients were informed of the investigational nature of this study and provided their written, informed consent. The study protocol was approved by the Ethics Committee of Osaka City University (#926).

Funding
This study was funded by Grants from the Japan Society for the Promotion of Science (KAKENHI, Nos. 25461992, 26461957, and 17K10559) to Shinichiro Asano et al. J Transl Med (2018) 16:87

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.
2. Couzin-Frankel J. Breakthrough of the year 2013, Cancer immunotherapy. Science. 2013;342(6165):1432–3.
3. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.
4. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Higuchi T, Tagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–5.
5. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M, Baba T, Yoshikoa Y, Kosaoka K, Konishi I. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol. 2011;141(3):338–47.
6. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Tagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2011;108(6):2490–5.
7. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.
8. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Higuchi T, Tagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–5.
9. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M, Baba T, Yoshikoa Y, Kosaoka K, Konishi I. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol. 2011;141(3):338–47.
10. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Tagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–5.
11. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Tagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–5.
12. Muenst S, Soysal SD, Gao F, Obermann EC, Dertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2015;139(3):667–76.
13. Sun S, Fei X, Mao Y, Wang X, Garfeld DH, Huang Q, Wang J, Yuan F, Sun L, Yu Q, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63(4):395–406.
14. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Drosner RA, Muraro MG, Zajac F, Zanetti R, Gillanders WE, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24.
15. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5(3):169–81.
16. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77.
17. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Tagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–5.
18. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
19. Greene FL, Sobin LH. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol. 2009;99(5):269–72.
20. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.
21. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):198–94.
22. Muenst S, Soysal SD, Gao F, Obermann EC, Dertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2015;139(3):667–76.
23. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, et al. Neoadjuvant versus adjuvant systemic therapy for patients with operable breast cancer: Cochrane Database Syst Rev. 2007;2:CD005502.
24. Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, et al. Neoadjuvant versus adjuvant systemic therapy for patients with operable breast cancer: Cochrane Database Syst Rev. 2007;2:CD005502.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2002;99(19):12293–7.
26. Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in patients with advanced melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.
27. Wolchok JD, Klerman HK, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ayani CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.
28. Toppalan SL, Szol M, McDermott DF, Kluger HM, Carvajal RD, Sharfan WH, Brahmer JR, Lawrence DF, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.
29. Montzjar P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharamgenom Pers Med. 2014;7:357–65.
30. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15.
useful evaluation system and handling protocol. Breast Cancer. 2006;13(3):232–5.

28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allied DC, Bartlett JM, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth-factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/Collage of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

29. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Renault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259–71.

30. Asano Y, Kashiwagi S, Goto W, Kurata K, Noda S, Takashima T, Onoda N, Tanaka S, Ohkawa Y, Hirakawa K. Tumour-infiltrating CDB to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016;103(7):845–54.

31. Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, Takashima T, Onoda N, Tomita S, Ohkawa Y, et al. Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS ONE. 2017;12(2):e0170634.

32. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanohiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–7.

33. Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci. 2012;103(4):626–31.

34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

35. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovitch N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.

36. Okazaki T, Chikuma S, Iwai Y, Fagaras S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212–8.

37. Dong H, Strome SE, Salomao DR, Tamura H, Harno F, Fries DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.

38. Houssami N, Macaskill P, van Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342–54.

39. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnecoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

40. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151–60.

41. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sauvés-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1(2):179–88.

42. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 2011;93(3):294–300.